RxDoctor Payments Data

Jephte Rodriguez Martinez, MD

General Practice · Mayaguez, PRNPI 1023190071

Payments from drug & device makers

$1,565in general payments, 2019–2025

Across 69 payments — averaging $22.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • PBG Puerto Rico LLC$344
  • AstraZeneca$337
  • Sanofi-aventis U.S. LLC$266
  • Hikma Pharmaceuticals USA$145
  • Merck$126
  • Exact Sciences$116
  • plus $231 from 5 others

What the payments were for

  • Food & beverage$1,565100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
PBG Puerto Rico LLC18$344
AstraZeneca18$337
Sanofi-aventis U.S. LLC11$266
Hikma Pharmaceuticals USA6$145
Merck3$126
Exact Sciences4$116
Boston Scientific1$71
Johnson & Johnson3$70
Boehringer Ingelheim3$56
E.r. Squibb & Sons, L.L.C.1$22
Pfizer Pharmaceuticals LLC1$12

How this compares

$1,565 in reported general payments places this provider in the 90th percentile of 3,586 general practice providers in Puerto Rico.

See all general practice providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$8,057
Medicare patients
19
Services billed
84

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol108$107,470
XareltoRivaroxaban67$75,552
EliquisApixaban56$62,067
TrulicityDulaglutide40$54,979
JanuviaSitagliptin Phosphate56$46,656
EntrestoSacubitril/Valsartan32$31,258
SynthroidLevothyroxine Sodium219$26,363
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate86$25,150
JardianceEmpagliflozin12$17,284
Candesartan Cilexetil110$15,035
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$13,489
LantusInsulin Glargine,hum.Rec.Anlog71$13,032
Janumet XrSitagliptin Phos/Metformin Hcl13$11,788
Soliqua 100-33Insulin Glargine/Lixisenatide11$11,637
JanumetSitagliptin Phos/Metformin Hcl18$11,577

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$337$114,388130 claims
Johnson & JohnsonXarelto$70$75,55267 claims
MerckJanuvia, Janumet Xr, Janumet$126$70,02187 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta, Stiolto Respimat$56$41,58455 claims
Sanofi-aventis U.S. LLCLantus, Soliqua 100-33$266$24,66982 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,586 general practice providers in Puerto Rico.

Other general practice in Mayaguez

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →